HK Innoen's 'K-Cab' Enters Malaysian Market... Expands to All Major Southeast Asian Countries

HK Innoen 'K-Cab Tablet' (Photo by HK Innoen)

[Asia Economy Reporter Lee Chun-hee] HK Innoen's gastroesophageal reflux disease new drug 'K-CAB Tablet' (active ingredient 'Tegoprazan') is entering the Malaysian market. With this, K-CAB has now entered all major Southeast Asian markets including Indonesia and Thailand.

HK Innoen announced on the 3rd that it recently signed a finished product export contract for K-CAB Tablet with Malaysian pharmaceutical company Pharmaniaga. Through this contract, Pharmaniaga will have exclusive distribution rights for K-CAB in Malaysia for five years after the product launch. The specific contract amount will remain confidential by mutual agreement between the two companies. Pharmaniaga is the largest pharmaceutical company in Malaysia and is expected to aggressively expand market share quickly through active sales after the product launch.

Through this contract, HK Innoen will export K-CAB to all six of the largest Southeast Asian economies, including Indonesia, Thailand, the Philippines, Vietnam, Singapore, and now Malaysia. The Southeast Asian market for peptic ulcer drugs was estimated at approximately $370 million (about 445.5 billion KRW) as of last year. With this contract, HK Innoen has established a foundation to enter 98% of the Southeast Asian market.

An HK Innoen official said, “With the entry into Malaysia, we have completed the foundation to target the entire Southeast Asian market,” adding, “Especially with the planned launch in China this year, it will be the first year that K-CAB actively targets the global market.”

This content was produced with the assistance of AI translation services.